The success of Epidiolex prompted several companies to attempt to create generic versions. Jazz Pharmaceuticals plc (NASDAQ: ...

Cybin pushes forward with Phase 3 depression trials after posting a narrower loss, while securing a $100M funding program.

Glass House attributed the solid results to cost cutting and lower production costs, along with increased same-store sales.

The Canadian cannabis producer missed revenue expectations but posted stronger margins as international sales surge.

Many businesses are grappling with declining wholesale prices, compliance costs and limited access to banking.

The U.S. cannabis market continues to be the largest in the world, but uncertainty around legalization and illicit market ...

The settlement could finally close the chapter on a five-year-old lawsuit alleging Tilray insiders secretly profited from ...

Republican Senators James Lankford of Oklahoma and Pete Ricketts of Nebraska filed a bill last week that would kill the 280e ...

The firm is betting big on harm-reduction technology, as the fentanyl crisis continues to drive demand for testing solutions.

MediPharm will keep its Ontario cannabis facility after Kensana missed deal conditions; company pivots to international focus ...

The Democratic governor called for: Changing how marijuana is taxed, closing a “loophole” and transitioning to wholesale ...

Fourth-quarter 2024 sales in the state reached $457 million, up 17% year over year, after 11-12% growth in the first three ...